Open-Label Safety Study in Adults and Adolescents with Haemophilia A with and without FVIII Inhibitors Switching Directly from Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Both

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Wheeler, Allison

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

09-12-2023

Trial Type:

Treatment

Protocol ID:

NCBH2302-FRONTIER5

National Clinical Trial ID:

NCT05878938

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available